Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 15/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 15/20 | 0.38 |
| ▸ | USP1 | O94782 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14883241 | 0.80 | HCRTR1 (0.34) | HCRTR1HCRTR2 | |
| SCHEMBL10109662 | 0.76 | HCRTR1 (0.42) | HCRTR1HCRTR2 | |
| SCHEMBL22040918 | 0.75 | NOTUM (0.43) | HCRTR1HCRTR2 | |
| SCHEMBL17145963 | 0.74 | MGLL (0.43) | HCRTR1HCRTR2 | |
| SCHEMBL807556 | 0.73 | CES2 (0.41) | — | |
| SCHEMBL18594654 | 0.72 | HCRTR1 (0.46) | HCRTR1HCRTR2 | |
| SCHEMBL14883176 | 0.71 | DPP4 (0.42) | HCRTR1HCRTR2 | |
| SCHEMBL18195988 | 0.71 | HCRTR1 (0.38) | HCRTR1HCRTR2 | |
| SCHEMBL12862574 | 0.69 | FAAH (0.48) | HCRTR1HCRTR2 | |
| SCHEMBL19732402 | 0.69 | GABRA1 (0.38) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020065613-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | WO | disclosed |
| US-9156819-B2 | 2-pyridyloxy-4-nitrile orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156819-B2 | 2-pyridyloxy-4-nitrile orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20130102619-A1 | 2-PYRIDYLOXY-4-NITRILE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2013-04-25 | — | — | US | disclosed |
| US-20130102619-A1 | 2-PYRIDYLOXY-4-NITRILE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2013-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102619-A1 | 2-PYRIDYLOXY-4-NITRILE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NTSR2 | HCRTR1 2/4885HCRTR2 1/4885USP1 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.